Randomized Trialhigh evidence
Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.
The New England journal of medicine·August 10, 2023·PMID 37366315
Why it mattersRetatrutide’s weight loss magnitude exceeds that of currently approved agents, suggesting a potential new option for obesity management. Its triple-agonist mechanism may offer metabolic benefits beyond weight loss, relevant for specialists managing obesity and related comorbidities.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled